Bluebird’s $2.8 million gene therapy becomes most expensive drug after US approval
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, US, August 29, 2020. REUTERS/Andrew Kelly/File Photo Register now for FREE unlimited access to Reuters.com register Aug 17 (Reuters) – The US Food and Drug Administration on Wednesday approved bluebird bio’s (BLUE.O) gene therapy for patients with a rare …
Bluebird’s $2.8 million gene therapy becomes most expensive drug after US approval Read More »